Literature DB >> 21904029

Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4.

Mutsuko Kukimoto-Niino1, Alexander Tokmakov, Takaho Terada, Naomi Ohbayashi, Takako Fujimoto, Sumiko Gomi, Ikuya Shiromizu, Masaki Kawamoto, Tomokazu Matsusue, Mikako Shirouzu, Shigeyuki Yokoyama.   

Abstract

The mitochondrial pyruvate dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA. PDC activity is tightly regulated by four members of a family of pyruvate dehydrogenase kinase isoforms (PDK1-4), which phosphorylate and inactivate PDC. Recently, the development of specific inhibitors of PDK4 has become an especially important focus for the pharmaceutical management of diabetes and obesity. In this study, crystal structures of human PDK4 complexed with either AMPPNP, ADP or the inhibitor M77976 were determined. ADP-bound PDK4 has a slightly wider active-site cleft and a more disordered ATP lid compared with AMPPNP-bound PDK4, although both forms of PDK4 assume open conformations with a wider active-site cleft than that in the closed conformation of the previously reported ADP-bound PDK2 structure. M77976 binds to the ATP-binding pocket of PDK4 and causes local conformational changes with complete disordering of the ATP lid. M77976 binding also leads to a large domain rearrangement that further expands the active-site cleft of PDK4 compared with the ADP- and AMPPNP-bound forms. Biochemical analyses revealed that M77976 inhibits PDK4 with increased potency compared with the previously characterized PDK inhibitor radicicol. Thus, the present structures demonstrate for the first time the flexible and dynamic aspects of PDK4 in the open conformation and provide a basis for the development of novel inhibitors targeting the nucleotide-binding pocket of PDK4.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21904029     DOI: 10.1107/S090744491102405X

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  10 in total

1.  Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site.

Authors:  Tiziana Masini; Barbara Birkaya; Simon van Dijk; Milon Mondal; Johan Hekelaar; Manuel Jäger; Anke C Terwisscha van Scheltinga; Mulchand S Patel; Anna K H Hirsch; Edelmiro Moman
Journal:  J Enzyme Inhib Med Chem       Date:  2016-07-19       Impact factor: 5.051

2.  Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.

Authors:  Shih-Chia Tso; Xiangbing Qi; Wen-Jun Gui; Cheng-Yang Wu; Jacinta L Chuang; Ingrid Wernstedt-Asterholm; Lorraine K Morlock; Kyle R Owens; Philipp E Scherer; Noelle S Williams; Uttam K Tambar; R Max Wynn; David T Chuang
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

Review 3.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

Review 4.  Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers.

Authors:  Nam Ho Jeoung
Journal:  Diabetes Metab J       Date:  2015-06       Impact factor: 5.376

Review 5.  Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?

Authors:  Wen Zhang; Shao-Lin Zhang; Xiaohui Hu; Kin Yip Tam
Journal:  Int J Biol Sci       Date:  2015-11-01       Impact factor: 6.580

6.  Global view of cognate kinase activation by the human pyruvate dehydrogenase complex.

Authors:  Elena L Guevara; Luying Yang; Barbara Birkaya; Jieyu Zhou; Natalia S Nemeria; Mulchand S Patel; Frank Jordan
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

7.  Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.

Authors:  Wenjia Zhang; Jing Su; Huadan Xu; Shanshan Yu; Yanan Liu; Yong Zhang; Liankun Sun; Ying Yue; Xiaoli Zhou
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

8.  Hsp90β knockdown in DIO mice reverses insulin resistance and improves glucose tolerance.

Authors:  Enxuan Jing; Pragalath Sundararajan; Ishita Deb Majumdar; Suwagmani Hazarika; Samantha Fowler; Angela Szeto; Stephane Gesta; Armando J Mendez; Vivek K Vishnudas; Rangaprasad Sarangarajan; Niven R Narain
Journal:  Nutr Metab (Lond)       Date:  2018-02-02       Impact factor: 4.169

Review 9.  Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications.

Authors:  Xiuxiu Wang; Xiaoyue Shen; Yuting Yan; Hongmin Li
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

10.  Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases.

Authors:  Xiaoli Zhou; Shanshan Yu; Jing Su; Liankun Sun
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.